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ARTICLE OPEN
Parkinson’s disease with restless legs syndrome—an in vivo
corneal confocal microscopy study
Mattias Andréasson 1,2,3✉, Neil Lagali 4, Reza A. Badian 5, Tor Paaske Utheim6, Fabio Scarpa7, Alessia Colonna7,
Stephan Allgeier 8, Andreas Bartschat8, Bernd Köhler 8, Ralf Mikut8, Klaus-Martin Reichert8, Göran Solders2,3,9, Kristin Samuelsson2,3,
Henrik Zetterberg10,11,12,13, Kaj Blennow10,11 and Per Svenningsson 1,2,3
Small fiber neuropathy (SFN) has been suggested as a trigger of restless legs syndrome (RLS). An increased prevalence of peripheral
neuropathy has been demonstrated in Parkinson’s disease (PD). We aimed to investigate, in a cross-sectional manner, whether SFN is
overrepresented in PD patients with concurrent RLS relative to PD patients without RLS, using in vivo corneal confocal microscopy
(IVCCM) and quantitative sensory testing (QST) as part of small fiber assessment. Study participants comprised of age- and sex-
matched PD patients with (n= 21) and without RLS (n= 21), and controls (n= 13). Diagnosis of RLS was consolidated with the
sensory suggested immobilization test. Assessments included nerve conduction studies (NCS), Utah Early Neuropathy Scale (UENS),
QST, and IVCCM, with automated determination of corneal nerve fiber length (CNFL) and branch density (CNBD) from wide-area
mosaics of the subbasal nerve plexus. Plasma neurofilament light (p-NfL) was determined as a measure of axonal degeneration. No
significant differences were found between groups when comparing CNFL (p= 0.81), CNBD (p= 0.92), NCS (p= 0.82), and QST
(minimum p= 0.54). UENS scores, however, differed significantly (p= 0.001), with post-hoc pairwise testing revealing higher scores
in both PD groups relative to controls (p= 0.018 and p= 0.001). Analysis of all PD patients (n= 42) revealed a correlation between
the duration of L-dopa therapy and CNBD (ρ=−0.36, p= 0.022), and p-NfL correlated with UENS (ρ= 0.35, p= 0.026) and NCS
(ρ=−0.51, p= 0.001). Small and large fiber neuropathy do not appear to be associated with RLS in PD. Whether peripheral small
and/or large fiber pathology associates with central neurodegeneration in PD merits further longitudinal studies.
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INTRODUCTION
The prevalence of restless legs syndrome (RLS) in Parkinson’s
disease (PD) has been reported as both higher1,2 and equal3,4 to
that in the normal population. Diagnosis is made clinically, based
on the characteristic history of a nocturnal urge to move the legs
in order to relieve an often associated sensory discomfort5.
The pathogenesis of RLS is not fully understood, but studies
have suggested different underlying pathophysiological mechan-
isms. These include disturbed cerebral iron metabolism, as
assessed by imaging6,7, cerebrospinal fluid8 and pathological9,10
studies, and disruption of central dopaminergic pathways as
evaluated by pathological studies11. Moreover, studies assessing
peripheral small fiber function in RLS have reported conflicting
results, with some favoring the presence of an RLS sub-phenotype
associated with small fiber neuropathy (SFN)12–14.
An increased prevalence of small15 and large fiber16,17
neuropathy has been demonstrated in PD, suggested in part to
reflect an underlying L-dopa-mediated disturbance of vitamin B12
metabolism16,17. However, considering reports of peripheral
neuropathy in L-dopa naïve PD patients18, and the detection of
deposits of alpha-synuclein (α-syn) in peripheral small nerve
fibers15, neuropathy has also been proposed to reflect an intrinsic
disease feature of PD.
In view of SFN as a possible contributing factor in the evolution
of RLS, we conducted a cross-sectional study hypothesizing that
PD with concurrent RLS is more highly associated with SFN
compared to PD without RLS. As part of the assessment, we
employed in vivo corneal confocal microscopy (IVCCM) as a novel
technique to visualize small fiber morphology.
RESULTS
Fifty-nine participants were included, of which three in the PD
with RLS (PD+RLS) group and one in the control group were
excluded during the study period. Reasons for exclusion consisted
of onset of stroke, bilateral cataract surgery, bilateral eye drop
treatment, and detection of a pre-existing peripheral neuropathy
when reviewing medical records. The final study population
included 55 participants: PD+RLS (n= 21), PD without RLS (PD
−RLS) (n= 21), and controls without PD (n= 13). The control
group was smaller than initially planned, due to subjects declining
to participate and/or fulfilling exclusion criteria.
Baseline characteristics
The study groups were well matched in terms of age and sex
(Table 1). All patients in the PD+RLS group fulfilled the
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International Restless Legs Syndrome Study Group (IRLSSG)
criteria5 for the diagnosis of RLS as part of the inclusion criteria.
Beyond this, a majority (81%) also exhibited a positive sensory
suggested immobilization test (SIT)19,20. The severity of RLS
symptoms in the PD+RLS group was severe, as reflected by a
median score of 21 points on the IRLSSG rating scale (IRLS). The PD
groups had comparable disease duration, levodopa equivalent
daily dose (LEDD), and duration of L-dopa treatment. The median
modified Hoehn and Yahr (mH&Y) stage was 2.0 in both PD
groups, although a significantly higher mean rank was evident in
the PD+RLS group (p= 0.039). In total, 45 participants underwent
bilateral (17 PD+RLS, 17 PD−RLS, and 11 controls) and 10
unilateral (4 PD+RLS, 4 PD−RLS, and 2 controls) IVCCM. Baseline
characteristics are outlined in Table 1.
Comparing peripheral nerve assessments between groups
A summary of the results from the battery of clinical, corneal, and
electrophysiological assessments of small and large nerve fibers is
reported in Table 2. A representative mosaic image of the corneal
subbasal nerve plexus is shown in Fig. 1.
No group differences were detected with regard to corneal
nerve fiber length (CNFL), (p= 0.81), or corneal nerve branch
density (CNBD), (p= 0.92). A difference in scores on the Utah Early
Neuropathy Scale (UENS) was observed between the three groups,
in which post-hoc testing revealed lower UENS scores in controls
relative to both PD groups after Bonferroni correction (PD+RLS:
p= 0.018, PD-RLS: p= 0.001). However, no difference in UENS
scores was demonstrated between PD+RLS and PD−RLS groups
(p= 0.78) (Table 2 and Fig. 1). Assessment of small and large fiber
function using quantitative sensory testing (QST) and nerve
conduction studies (NCS) did not reveal any significant differences
between the three study groups (Table 2).
Results from the quantification of cells in the subbasal corneal
nerve plexus are shown in Table 2. No significant differences in the
density of mature dendritic cells (DCs), immature DCs, and
globular cells were seen between groups. When comparing the
proportions of inflammatory cell types in the subbasal nerve
plexus, a borderline-significant tendency (p= 0.050) was seen,
suggesting a difference in cell composition between the groups,
possibly favoring an increased proportion of globular cells in the
PD+RLS group (Table 2).
Table 1. Demographic, clinical, and biochemical characteristics of the study population.
PD+RLS (n= 21) PD−RLS (n= 21) CL (n= 13) p
Age (years) 69.4 (5.9) 69.2 (6.0) 69.7 (6.6) 0.93a
Male/female 15/6 15/6 9/4 0.99b
Smoking (n, %yes) 3 (14.3) 2 (9.5) 2 (15.4) 0.89c
RLS heredity (n, %yes) 8 (38.1) 4 (19.0) 1 (7.7) 0.14c
PD heredity (n, %yes) 7 (33.3) 9 (42.9) 1 (7.7) 0.093b
B12 or multivitamins (n, %yes) 13 (61.9) 12 (57.1) 3 (23.1) 0.068b
B6 or multivitamins (n, %yes) 3 (14.3) 5 (23.8) 3 (23.1) 0.76c
Coffee consumption (cups/day) 2.5 (1.6) 2.2 (1.4) 3.7 (2.4) 0.12a
s-Ferritin (μg/L) [30–350] 159 (86.6) 159 (105) 186 (147) 0.94a
p-Homocysteine (μmol/L) [5–15] 15.9 (4.7) 15.0 (3.6) 15.5 (3.4) 1.0a
s-MMA (μmol/L) [<0.37] 0.18 (0.06) 0.17 (0.06) 0.17 (0.03) 0.90a
s-Folate (nmol/L) [>7] 22.8 (13.7) 19.6 (11.8) 18.2 (8.3) 0.67a
p-Pyridoxal-5ʹ-phosphate (nmol/L) [20–122]d 54.5 (32.7) 77.5 (68.9) 45.9 (26.5) 0.14a
p-NfL (pg/mL) 6.3 (3.8) 6.2 (4.2) 6.1 (4.1) 0.95a
PD-specific variables
Motor duration (years) 7.9 (4.1) 7.5 (4.4) – 0.66e
L-dopa duration (years) 5.1 (3.8) 4.6 (4.6) – 0.42e
mH&Y (stage) 2.3 (0.4) 2.1 (0.5) – 0.039e
LEDD (mg) 725 (360) 684 (308) – 0.96e
No L-dopa treatment (n, %yes) 1 (4.8) 1 (4.8) – 1.0c
RLS-specific variables
RLS duration (years) 10.6 (11.3) – – –
IRLS (p) 18.5 (7.9) – – –
Positive SIT testf (n, %yes) 17 (81.0) – – –
Data are presented as mean (standard deviation) for numerical, and proportions (%) for categorical variables. Positive SIT was defined as a mean leg discomfort
score >11. Heredity was defined as a positive family history of suspected PD or RLS.
PD+RLS Parkinson’s disease with restless legs syndrome, PD−RLS Parkinson’s disease without restless legs syndrome, CL controls, B12/B6 or multivitamins
participants reporting intake of either multivitamins or vitamin B12/B6, p plasma, s serum, MMA methylmalonic acid, NfL neurofilament light, mH&Y modified
Hoehn and Yahr, LEDD levodopa equivalent daily dose, IRLS International Restless Legs Syndrome Study Group Rating Scale, SIT suggested immobilization test.




dIn one blood sample, light protection was reported as insufficient.
eMann–Whitney U-test.
fOne participant reported discomfort from both arms and legs during assessment.
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Looking solely at PD patients that underwent bilateral IVCCM
(n= 34), no significant differences in CNFL (p= 0.19) or CNBD
(p= 0.10) were evident when comparing both eyes within-subjects,
using the paired-samples T-test. Comparing PD patients with
unilateral (n= 8) to PD patients with bilateral IVCCM (n= 34), no
significant group differences were observed in mean CNFL
(p= 0.44) or mean CNBD (p= 0.34).
Associations between peripheral nerve assessments and PD
burden
To assess potential associations between peripheral nerve fiber
pathology and indirect measures of overall PD burden, a subgroup
analysis was performed in all PD patients (n= 42). Using the age-
adjusted partial Spearman’s rank correlation test, an association
was found between corneal parameters (CNFL and CNBD) and the
duration of L-dopa therapy (ρ=−0.34, p= 0.031 and ρ=−0.36,
p= 0.022, respectively); however, only the association with CNBD
was significant when controlling for both age and sex (Fig. 2). A
correlation, after adjusting for age and sex, was also observed
between the electroneurography index (ENeG-Ix) and plasma
neurofilament light (p-NfL) (ρ=−0.51, p= 0.001, Fig. 3a). More-
over, p-NfL exhibited an age- and sex-adjusted correlation with
UENS scores (ρ= 0.35, p= 0.026), (Fig. 3b). Finally, the mH&Y
stage correlated significantly with the warmth (ρ= 0.35, p= 0.028)
and cold (ρ= 0.37, p= 0.019) thresholds of the hand, adjusting for
age and sex. All tested correlations are summarized in Supple-
mentary Table 1.
Markers of methionine cycle metabolism
No significant group differences were observed when comparing
levels of p-pyridoxal-5-phosphate (vitamin B6), s-methylmalonic
acid (MMA), s-folate, and p-homocysteine (Table 1). The median
levels of these parameters were all within the normal range in
patients with PD. Notably, a considerable proportion (60%) of
patients with PD reported intake of vitamin B12 or multivitamin
supplements.
A subgroup analysis was performed in the entire PD group
(n= 42), comparing patients with (n= 25) and without (n= 17)
any B-vitamin supplementation. No significant differences with
regard to peripheral nerve parameters were demonstrated
between the two groups (Table 3). Notable significant differences
were evident with regard to the duration of L-dopa therapy
(p= 0.002) and disease duration (p= 0.001), suggesting a more
advanced disease in patients receiving B-vitamin supplementa-
tion. Demographic data together with clinical, corneal, and
electrophysiological data for these two groups are shown in
Table 3.










UENS (p) 5.8 (4.1) 6.1 (2.4) 2.7 (2.8) 0.001
Neurophysiological assessments
ENeG-Ix −0.70 (0.95) −0.64 (0.82) −0.66 (0.64) 0.82
WT hand (°C) 2.6 (1.7) 2.4 (1.0) 2.4 (1.7) 0.84
CT hand (°C) 2.5 (1.9) 1.9 (1.1) 1.7 (0.47) 0.74
WT foot (°C) 10.9 (4.1) 10.8 (4.5) 9.7 (4.2) 0.71
CT foot (°C) 8.5 (10.0) 7.7 (6.9) 5.0 (2.8) 0.54
In vivo corneal confocal microscopy
CNFL (mm/mm2) 17.5 (3.8) 16.9 (3.1) 17.6 (3.9) 0.81
CNBD (no/mm2) 105 (34.6) 106 (38.7) 111 (36.5) 0.92
Mature DCs
(proportion, %)
16.0 (11.8) 18.0 (10.1) 21.5 (14.9) 0.56
Immature DCs
(proportion, %)
69.5 (17.7) 70.1 (16.4) 72.5 (16.7) 0.89
Globular cells
(proportion, %)
14.5 (16.2) 12.0 (15.6) 6.0 (4.2) 0.050
Mature DCs
(density, cells/mm2)
6.1 (6.0) 9.0 (8.9) 10.7 (10.5) 0.58
Immature DCs
(density, cells/mm2)
29.6 (24.8) 35.1 (29.9) 53.8 (51.4) 0.54
Globular cells
(density, cells/mm2)
5.9 (10.4) 4.9 (9.0) 2.1 (1.4) 0.19
Data are presented as mean (standard deviation). No significant differences
between PD patients with and without RLS were observed in the
assessments of small fiber neuropathy. A higher UENS score was observed
in PD groups relative to controls.
PD+RLS Parkinson’s disease with restless legs syndrome, PD−RLS Parkin-
son’s disease without restless legs syndrome, CL controls, UENS Utah Early
Neuropathy Scale, ENeG-Ix electroneurography index, WT warmth thresh-
old, CT cold threshold, CNFL corneal nerve fiber length, CNBD corneal nerve
branch density, DCs dendritic cells.
In bold—indicates p-value ≤ 0.05.
aAll analyses performed with Kruskal–Wallis H-test except CNFL, in which



















H = 14.2, p = 0.001 (Kruskal-Wallis H-test)
b
Fig. 1 Group comparisons of UENS scores and representative mosaic image of the corneal subbasal nerve plexus. Comparison of UENS
scores (a) between study groups. Boxplot showing center line (median), interquartile range (box length), whiskers (1.5 × interquartile range)
and outliers. b Left: mosaic image from patient with PD and RLS showing traced nerve paths. Scale bar= 500 μm. Right: magnified region
showing detailed nerve paths (green) and branching points (red). Scale bar= 100 μm.
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DISCUSSION
The main finding of this study is that SFN, as assessed by IVCCM,
QST, and UENS, appears not to be associated with RLS in PD.
Furthermore, we could neither demonstrate any association
between RLS in PD and large fiber neuropathy, as assessed by
NCS (Table 2).
A previous study also addressed a possible association between
peripheral neuropathy and PD with RLS in a cross-sectional
manner, similarly with negative findings21. However, the assess-
ments in that study consisted of NCS and UENS, without further
evaluation of small fiber function or morphology21. Since SFN has
been proposed as an intrinsic feature of PD15, we believe the
present study adds further knowledge to the possible clinical
correlates of SFN in PD. In other words, RLS does not seem to
represent a phenotypic expression of SFN in PD.
An important part of the present study was to ensure a reliable
diagnosis of RLS. RLS mimics, such as leg cramps, akathisia, inner
restlessness, and wearing-off phenomenon, are important to
differentiate when diagnosing RLS in PD22. In the present study, all
PD+RLS patients fulfilled the IRLSSG criteria5, and common
pharmacological and metabolic triggers of RLS were part of the
0
1.0






























Fig. 3 Associations between p-NfL and functional peripheral
nerve parameters. Associations between measures of large fiber
function, as assessed by nerve conduction studies (a) and UENS (b),
and p-NfL. Correlation coefficients and p-values calculated with
partial Spearman’s rank order correlation adjusting for age and sex
(ENeG-Ix: ρ=−0.51, p=0.001; UENS: ρ=0.35, p=0.026). p-Values not






































Fig. 2 Associations between corneal parameters and L-dopa
therapy. The duration of L-dopa therapy associates with CNBD (a)
and CNFL (b). Correlation coefficients and p-values calculated with
partial Spearman’s rank order correlation adjusting for age and sex
(CNBD: ρ=−0.36, p=0.022), and age (CNFL: ρ=−0.34, p=0.031),
respectively. p-Values not adjusted for multiple comparisons.
Table 3. Characteristics of subgroup analysis comparing PD patients






Age (years) 69.1 (5.4) 69.6 (6.6) 0.53a
Male/female 19/6 11/6 0.50b
p-Homocysteine
(μmol/L) [5–15]
14.6 (4.0) 16.7 (4.3) 0.078a
p-NfL (pg/mL) 7.0 (4.6) 5.1 (2.6) 0.11a
PD-specific variables
Motor duration (years) 9.2 (4.3) 5.6 (3.0) 0.001a
L-dopa duration
(years)
6.2 (4.3) 2.8 (3.0) 0.002a
mH&Y (stage) 2.3 (0.48) 2.1 (0.42) 0.22a
LEDD (mg) 749 (285) 640 (390) 0.12a
No L-dopa treatment
(n, %yes)
0 (0) 2 (11.8) 0.16b
RLS study diagnosis
(n, %yes)
13 (52.0) 8 (47.1) 0.75c
Peripheral nerve parameters
UENS (p) 6.1 (3.3) 5.8 (3.4) 0.70a
ENeG-Ix −0.85 (0.95) −0.41 (0.72) 0.10a
WT hand (°C) 2.7 (1.6) 2.3 (1.1) 0.73a
CT hand (°C) 2.3 (1.8) 2.0 (1.0) 0.91a
WT foot (°C) 11.7 (3.9) 9.6 (4.5) 0.21a
CT foot (°C) 8.9 (9.4) 7.0 (7.2) 0.56a
CNFL (mm/mm2) 17.0 (3.1) 17.6 (4.0) 0.57d
CNBD (no/mm2) 103 (28.0) 110 (46.5) 0.52d
Data are presented as mean (standard deviation) for numerical, and
proportions (%) for categorical variables. A significantly longer disease
duration and duration of l-dopa exposure was observed in the group
receiving vitamin B supplements. No significant differences were observed
with regard to peripheral nerve parameters.
PD+B-vit Parkinson’s disease with vitamin B6 and/or B12 and/or multi-
vitamin supplementation, PD−B-vit. Parkinson’s disease without vitamin B
supplementation, NfL neurofilament light, mH&Ymodified Hoehn and Yahr,
LEDD levodopa equivalent daily dose, UENS Utah Early Neuropathy Scale,
ENeG-Ix electroneurography index, WT warmth threshold, CT cold thresh-
old, CNFL corneal nerve fiber length, CNBD corneal nerve branch density.
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study exclusion criteria. Furthermore, the sensory SIT was
employed in the PD+RLS group, reaching a positive outcome in
81% of the patients (Table 1). The sensory SIT has been shown to
have a 91% sensitivity and 72% specificity for RLS in the context of
PD, when performed during symptomatic RLS periods20. Con-
sidering the high probability that not every PD+RLS patient was in
an active symptom period at the time of testing, we believe the
81% test positivity is supportive of a true RLS diagnosis in the PD
+RLS group. We also believe the comprehensive diagnostic
evaluation performed in the PD+RLS group consolidates the
reliability of the main study result, that RLS in PD appears not to
be associated with small or large fiber neuropathy.
In the present study, we could not detect any significant
differences in measures of peripheral neuropathy in patients with
PD, as assessed by IVCCM, QST, and NCS, relative to controls.
However, a significantly higher UENS score was seen in both PD
groups relative to controls (Table 2). These results are in contrast
to previous studies, where an increased prevalence of large fiber
neuropathy in PD has been reported, when evaluated with both
NCS and clinical rating scales16,23,24. In those studies, neuropathy
was suggested to be associated with alterations in the vitamin
B12-dependent methionine cycle, mediated by chronic exposure
to L-dopa and thus associated with elevated levels of
p-homocysteine and s-MMA16,23,24. In the present study, 60% of
the PD patients were taking vitamin B12 or multivitamin
supplements, and the median levels of p-homocysteine and
s-MMA were within normal range. In order to address possible
confounding effects of B-vitamin supplementation, a subgroup
analysis comprising all PD patients (n= 42) was performed. As
outlined in Table 3, no significant differences in corneal,
electrophysiological or clinical assessments of peripheral nerves
were found between PD patients with and without B-vitamin
supplementation. However, a significantly longer disease duration
(p= 0.001) and duration of L-dopa exposure (p= 0.002) was
evident in the B-vitamin supplemented group. Thus, we still
cannot exclude the presence of a protective, and confounding,
effect of B-vitamin supplementation that contributed to the
absence of a significantly higher prevalence of peripheral
neuropathy in the more advanced disease group. This finding
may be of interest, and motivates further investigation of possible
protective effects of vitamin B12 supplementation with regard to
the development of peripheral neuropathy in PD.
SFN has been demonstrated in skin biopsies from L-dopa naïve
patients18. Furthermore, cutaneous SFN in PD has, in some studies,
been reported as asymmetrical, lateralizing with the side more
affected by parkinsonism18,25. Considering these studies, together
with the reported findings of α-syn deposits in autonomic and
somatosensory small nerve fibers, the concept of peripheral
neurodegeneration intrinsic to PD has been suggested15. Surpris-
ingly in the present study, in line with findings reported for large
fiber neuropathy, no significant differences in SFN, as assessed by
IVCCM and QST, were found in the PD groups relative to controls.
Limitations of this study, however (discussed below), must be
considered.
The human cornea is heavily innervated by small C- and Aδ
nerve fibers, originating from the trigeminal nerve26. In diabetes
mellitus, the visualization of small nerve fiber pathology in
the corneal subbasal nerve plexus has been proposed as a
surrogate marker of general diabetic peripheral neuropathy27.
Here, we chose to present large mosaic depictions of the subbasal
nerve plexus. Recent studies have proposed imaging and analysis
of a wide area of the subbasal nerve plexus to be advantageous,
by reducing inherent biases associated with subjectively imaging,
and selecting, typically only a few single microscope frames for
nerve analysis (each frame representing 0.2% of the total area of
the subbasal nerve plexus). In a study examining patients with
multiple sclerosis, mosaics with a mean size of 1.29 mm2
(corresponding to the area of 7.7 individual microscope frames)
were produced28. In a previous study with healthy and type 2
diabetes participants, we reported a mean mosaic size of 6.0 mm2
(37 frames)29, whereas in the present study the mean mosaic size
was 7.7 mm2 (48 frames). Moreover, the present IVCCM methods
were fully automated, avoiding observer-dependent biases in
image selection and analysis.
Only a few previous studies have assessed corneal nerve
parameters in PD, with conflicting results. A study investigating
26 patients with PD, with varying disease duration, detected
significantly increased CNBD and CNFL relative to controls,
correlating negatively with motor scores and autonomic symp-
toms30. In that study, 4–6 single confocal microscope image
frames per eye (non-mosaic) were manually selected. By contrast,
in a study consisting of 26 early PD patients with minimal L-dopa
exposure, significantly decreased CNBD and CNFL were reported
relative to controls, with the authors proposing the corneal
alterations may reflect a preclinical neuropathy in PD31. In that
study, 4–8 single images frames per eye were manually selected
for analysis.
The present study did not confirm these prior discriminative
findings in corneal parameters with respect to controls, but
instead detected similar CNBD and CNFL in all three groups
(Table 2). Even when comparing controls to the PD group as a
whole (n= 42), no differences were detected (CNFL: p= 0.84;
CNBD: p= 0.71). Importantly, the present study was not primarily
designed to assess the power of CNBD and CNFL to discriminate
between PD and controls. Nevertheless, in the context of previous
studies in PD, we believe a strength of the present study is the use
of large mosaic depictions of the subbasal nerve plexus. Prior
studies examining PD patients with IVCCM quantified 10–12% of
the subbasal plexus area quantified in this study, and used manual
image selection and semi-manual nerve quantification methods.
Therefore, we believe the present study, using robust methodol-
ogy, suggests that CNBD and CNFL are not suitable as
discriminative diagnostic assessments in moderate PD.
In diabetes mellitus, an increased proportion of mature DCs in
the subbasal nerve plexus has been reported and was suggested
to reflect a corneal immune-activation associated with diabetic
disease32. The present study provided no evidence for immune
activation in the corneal subbasal nerve plexus in patients with
PD. The least prevalent cell type detected in all groups were the
globular cells. Although the median globular cell density was
similar among groups, the Kruskal–Wallis H-test indicated a
borderline-significant (p= 0.050) proportional difference between
the three groups, possibly suggestive of an increased relative
proportion of globular cells in the PD+RLS group (Table 2). The
biological implication of this finding is uncertain, and as of now,
the role of this cell type is not known.
Peripheral neuropathy has been suggested as an independent
marker of a more severe PD phenotype, associated with an
increased burden of both motor and non-motor symptoms33. In
the subgroup analysis (n= 42), we examined if measures of small
and/or large fiber pathology were associated with indirect markers
of general disease progression (Figs. 2 and 3). We believe the
demonstrated associations between corneal parameters and the
duration of L-dopa therapy may merit future studies evaluating
the potential of monitoring small fiber morphology, as assessed
by IVCCM, as a marker of ongoing central neurodegeneration.
However, in such studies it will be important to account for
confounding effects of L-dopa-mediated alterations of the
methionine cycle. Thus, inclusion of careful analyses of vitamin
B6, B12, s-MMA, and p-homocysteine are required; in the present
study, 60% of patients with PD were taking supplements and
median p-homocysteine levels were normal (Table 1).
Plasma NfL is a marker of axonal degeneration34, and has been
suggested to be associated with both PD progression35 and
disease activity in hereditary peripheral neuropathy36,37. Indeed,
significant associations were demonstrated in the present study
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between p-NfL and ENeG-Ix and UENS, even after adjusting for
age and sex (Fig. 3). Considering p-NfL also correlated significantly
with mH&Y, after adjustment for age and sex (ρ= 0.39, p= 0.013),
we believe p-NfL might reflect both central and peripheral
ongoing axonal neurodegeneration in PD.
The small study group constitutes the main limitation of this
study. Importantly, the control group was smaller than the two PD
groups, and as a result, comparisons relative to controls might
have both under- and overestimated group differences. However,
the main aim of this study was to assess whether SFN is
overrepresented in PD+RLS relative to PD−RLS, and thus we
believe our main finding was not affected by the smaller control
group. Considering reports of asymmetrical presentations of SFN
in PD18,25, the unilateral QST, in contrast to the bilateral UENS,
might have underestimated SFN in PD. Since the tested side was
randomly chosen, this should not have affected comparisons
between PD groups but rather comparisons relative to controls.
Similarly, the randomly chosen side for motor and sensory NCS
might also have contributed to the absence of large fiber
neuropathy relative to controls in the entire PD group. The
reliability of RLS diagnosis is important when interpreting the
main study results. As discussed, four patients exhibited a
negative sensory SIT and thus a repeated test, during a
symptomatic period, could have been done to further consolidate
the diagnosis in these patients. The subgroup analysis, encom-
passing all PD patients (n= 42), did not constitute the main aim of
this study and was thus considered explorative in nature.
Therefore, Bonferroni adjustments for multiple comparisons in
the correlation analyses were not performed and as such, type 1
errors must be taken into consideration when interpreting
these data.
RLS in PD does not appear to be associated with small or large
fiber neuropathy as assessed by IVCCM, QST, UENS, and NCS. The
potential of objective functional and structural assessments of
peripheral small and large fibers, as a surrogate marker of PD
progression, warrants further evaluation in longitudinal studies
accounting for both the reported asymmetrical presentations of
peripheral neuropathy in PD, and the possible confounding role of




All participants gave written informed consent and the study was
approved by the regional ethical board of Stockholm, Sweden (ref. nr
2018/264-31/2 (2019-03158)). Patient-related investigations were under-
taken in accordance with the Helsinki Declaration.
Participants were recruited between the spring of 2018 and autumn of
2019. Patients with PD followed at the outpatient clinic at Center for
Neurology and Karolinska University Hospital, Stockholm, were invited to
participate if reporting symptoms indicative of RLS. We also used a written
advertisement, posted at the local patients’ organization website, inviting
patients with PD and RLS symptoms from the Stockholm region to
participate. Patients meeting criteria were included and constituted the PD
+RLS group. Controls and PD patients not meeting RLS criteria, and
matched for age, sex, and disease duration, were also invited to participate
during visits to the outpatient clinic. All participants were aged 50–80 years
and had at least one eye free from previous corneal trauma, surgery, or
ongoing eye drop treatment. Accompanying persons or spouses
constituted the control group.
Inclusion criteria for patients consisted of a diagnosis of clinically
probable PD according to the Movement Disorders Society criteria38 and
RLS according to the IRLSSG criteria5 where applicable. Exclusion criteria
included a known diagnosis of diabetes mellitus, rheumatoid arthritis,
polyneuropathy, iron deficiency anemia, or renal failure (p-creatinine
>150 µmol/L); heavy alcohol consumption (≥168 (men) or ≥108 (women) g
alcohol/week)39; ongoing medication with selective serotonin reuptake
inhibitors, serotonin–norepinephrine reuptake inhibitors, tricyclic antide-
pressants, or neuroleptic drugs at the time of RLS onset.
Clinical assessments
Clinical information including smoking habits, alcohol consumption,
heredity, and current medication was obtained through oral history and
review of medical records. LEDD was calculated as previously described40.
Disease duration was defined as time since motor symptom onset. Clinical
examination included mH&Y41,42 staging and the UENS43, a clinical rating
scale sensitive for the detection of SFN. The severity of RLS symptoms was
evaluated with the IRLS44.
Biochemistry
Fasting venous blood samples were collected and analyzed at Karolinska
University Laboratory according to clinical routine. The tests included
p-homocysteine, s-MMA, s-folate, s-cobalamin, s-ferritin, p-glucose, and
b-HbA1c. Analysis of p-pyridoxal-5-phosphate (vitamin B6) was per-
formed at Sahlgrenska University Hospital, Gothenburg. Plasma NfL
concentration was measured using an in-house single molecule array
(Simoa) assay, as described previously in detail45, at Sahlgrenska
University Hospital, Mölndal. All p-NfL analyses were performed in one
run, using the same batch of reagents, by board-certified laboratory
technicians blinded to the clinical information.
Sensory suggested immobilization test
The PD+RLS group was further assessed with the sensory SIT19,20. Patients
were observed in the evening, between 8 PM and 9 PM, lying down in a
45° recumbent position and instructed to move as little as possible with
legs extended. Patients were asked every 10min to indicate their
perceived severity of leg discomfort, using a visual analog scale of
0–100, generating seven individual values for each participant. A mean leg
discomfort score >11 was used as supportive of RLS diagnosis. This cutoff
value has previously been evaluated and proposed as appropriate in the
context of RLS diagnosis in PD20.
Neurophysiology
Electrodiagnostic testing and QST took place at the Department of
Neurophysiology, Karolinska University Hospital. Motor NCS were carried
out unilaterally in the median, peroneal, and tibial nerves, and sensory NCS
unilaterally in the median and sural nerves with surface electrodes, using
Viking EDX (Cephalon A/S; Denmark). The tested side was chosen
randomly and care was taken to make all recordings at a skin temperature
of >32 °C. Twelve parameters were chosen to calculate an index (ENeG-Ix)
as previously described46. In short, six parameters represent conduction
velocities (3 motor + 3 sensory, 3 upper + 3 lower extremity) and six
represent amplitudes (3 compound muscle action potentials + 3 sensory
nerve action potentials, 3 upper + 3 lower extremity). To achieve a more
Gaussian distribution, the natural logarithms of the amplitudes were used.
The ENeG-Ix is then calculated as the mean deviation (in SD) from normal
controls standardized for age and height. The ENeG-Ix thus reflects
peripheral large fiber function, correlating negatively with the degree of
neuropathy. An index value that differs >0.72 SD from normal is considered
abnormal. For details in ENeG-Ix calculation, see Solders et al.46.
QST was performed by the method of levels unilaterally over the thenar
muscles in the hand and on the lateral part of the foot using Medusa TSA II
(Cephalon A/S; Denmark). The probe operating by the Peltier principle has
a rectangular surface of 2.5 × 5.0 cm. The baseline temperature of the
probe was set to 32 °C. Five cold and five warm stimuli were delivered with
a rise or fall in temperature of 1 °C/s. The participants were instructed to
press a handheld button as soon as she/he experienced a sensation of cold
or warmth, thereby also returning the probe to 32 °C. The perceptions
thresholds were determined as the difference between 32 °C and the mean
perception level of the five stimuli for cold (CT) and warmth (WT),
respectively.
In vivo corneal confocal microscopy
All participants underwent IVCCM bilaterally, or unilaterally if one eye
met exclusion criteria. The central corneal subbasal nerve plexus was
imaged as previously described47. Briefly, a topically anesthetized eye
was examined with the Heidelberg Retinal Tomograph 3 laser-scanning
confocal microscope with the Rostock Corneal Module (Heidelberg
Engineering, Germany). A single examiner performed all eye scanning,
recording images of the subbasal nerve plexus across a wide area of the
plexus using the built-in fixation light to access paracentral regions and
continually adjusting the focus to the plexus depth. Mosaics were
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generated with an automated computer algorithm to select nerve plexus
images from the recorded data using tissue classification48 and to stitch
together adjacent images. Depth variations of subbasal nerve fiber paths
were mapped onto a single two-dimensional mosaic image47. A separate
automated algorithm was used for detection and tracing of nerve paths
and branching points, from which the mean values of CNFL (total nerve
fiber length in a mosaic divided by the mosaic area, expressed in mm/
mm2) and CNBD (total number of nerve branching points divided by the
mosaic area, expressed as the number of branching points per mm2)
were calculated49,50. Averaged values between both eyes were used
where applicable.
In addition, two independent trained observers performed a morpho-
logical characterization and manual quantification of cells present in the
subbasal nerve plexus. All cells present in the mosaics were counted and
classified by both observers, purely by visual morphology as mature DCs,
immature DCs, and globular cells, as previously described32. The
quantitative results were averaged between the two observers and across
both eyes per participant where applicable, generating proportional and
density data for each cell type in each study participant. The observers
were masked to the identity of each mosaic image.
Statistical analysis
Categorical variables are presented as proportions. The distribution of
continuous variables was tested for normality by using the Shapiro-Wilk test
and assessment of skewness. Numerical variables are presented as mean
(standard deviation). For comparison between groups, Mann–Whitney U-
test and Kruskal–Wallis H-test were used for numerical variables not
meeting assumptions for parametric testing. Independent T-test and one-
way analysis of variance was used for comparison of normally distributed
variables between groups, when the assumption of homoscedasticity was
met. The paired-samples T-test was performed in dependent observations,
after analyzing the differences between the dependent variables. In the
absence of outliers and when normal distribution of the differences was
evident, as assessed by skewness and the Shapiro-Wilk test, the paired
T-test was performed. Categorical variables were compared using chi-
square test, and Fisher’s exact test when the assumption of minimum
expected values was not met. Correlation analyses for non-normally
distributed variables were done using partial Spearman’s rank order
correlation. A two-tailed p-value of < 0.05 was considered significant. All
statistical analyses were performed using IBM SPSS Statistics for Windows,
version 25.0 (IBM Corp., Armonk, N.Y., USA).
Reporting summary
Further information on research design is available in the Nature Research
Reporting Summary linked to this article.
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